Johnathan M. Lancaster, MD, PhD
Director, Center for Women's Oncology, Chair, Department of Women's Oncology
H. Lee Moffitt Cancer Center
12902 Magnolia Drive - MCC
Tampa,
FL
USA
33612-9497
Papers:
54 - Featured Poster
Development of a Rucaparib response signature that shows in vitro predictive value to the PARP inhibitors, ABT-888 and Olaparib in ovarian cancer cells
146 - Poster Session A
The BCL2 antagonist of cell death (BAD) signaling pathway and phospho-BAD protein levels are associated with triple-negative breast cancer clinical development and clinical outcome
214 - Poster Session A
BCL2 antagonist of cell death (BAD) gene sequence and functional analysis of phosphorylation sites in ovarian cancer
299 - Poster Session A
Copy number variation and mutations associated with ovarian cancer chemoresponse
301 - Poster Session A
HSP90 inhibition decreases ovarian cancer cell proliferation and potentiates platinum sensitivity
341 - Poster Session A
Association between endometrioid endometrial cancer (EC) risk classification and gene expression in The Cancer Genome Atlas (TCGA) dataset
455 - Poster Session B
Polyphyllin D, a Chinese herb, potentiates cisplatin-induced death in ovarian cancer cell lines
525 - Poster Session B
Correlation of survival-stratified proteomic and curated gene data reveal a three protein biomarker panel that predicts long-term survival of patients with primary epithelial ovarian cancer